Commonly Used Type 2 Diabetes Medication Linked to Higher Rate of Heart-Related Conditions

Commonly used diabetes drugs may elevate risk for cardiovascular events for some

Commonly used sulfonylureas were associated with an up to 13% increase in risk for major adverse CV events vs. dipeptidyl-peptidase IV inhibitors in patients with type 2 diabetes and moderate CV risk, researchers reported.“Sulfonylureas remain a common choice of pharmacotherapy of type 2 diabetes, due in part to their low cost and glucose-lowering potency. In the past, individual

Commonly used type 2 diabetes medication linked to higher rate of heart-related conditions

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit other targets.

Cardiovascular Risks Resurface Old Concerns About Sulfonylureas for T2D

(MedPage Today) -- Sulfonylureas were flagged for excess cardiovascular risk when used for additional glucose lowering in type 2 diabetes (T2D) in an observational comparative effectiveness study. As second-line therapies atop metformin, individual...

Common type 2 diabetes drugs compared—study finds higher cardiovascular risk for glipizide

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit other targets. The study examined nationwide data from nearly 50,000 patients treated with different sulfonylureas and found that glipizide—the most widely used drug in the U.S. within this category—was linked to higher incidence of heart failure, …

Common Type II Diabetes Drug Linked to Higher Cardiovascular Risk

A study from Mass General Brigham has shown that glipizide, a widely prescribed drug for type II diabetes, can increase the five-year risk of major cardiovascular events by 13% compared to other drugs used to manage the condition. Published in JAMA Network Open, the study analyzed data from nearly 50,000 patients with type II diabetes and moderate cardiovascular risk across the U.S.  “Patients with type II diabetes are at heightened risk of adve…